SunRock Biopharma

Executive Summary

SunRock Biopharma is a preclinical-stage Spanish biotechnology company founded in 2017 and headquartered in Barcelona. The company specializes in developing innovative antibody-based therapeutics for highly invasive tumors with significant unmet medical needs. Operating under an open innovation model, SunRock translates academic research into immunotherapeutic solutions. As a private company with no disclosed funding, valuation, or pipeline details, SunRock is at a very early stage of development. While its focus on antibody biologics targeting aggressive cancers aligns with industry trends, the lack of public data on specific programs, financial backing, or partnerships limits assessment of its potential. The company faces typical preclinical risks, including scientific validation, regulatory hurdles, and capital requirements.

Upcoming Catalysts (preview)

• H2 2026IND Filing for Lead Antibody Candidate30% success
• 2026Series A Financing Round40% success
• 2026Research Collaboration or Licensing Deal25% success